Epigene Therapeutics Information

The Epigene Therapeutics team is dedicated to advancing novel epigenetic modulators for the targeted treatment of cancer. Epigene Therapeutics has generated six distinct chemical series/scaffolds from which a portfolio of novel epigenetic modulators is advancing through preclinical development. The lead molecule, NEO2734, currently in late pre-IND stage of development, is an orally-bioavailable, first-in-class dual Bromodomain and Extra-Terminal domain (BET) and Cyclic AMP response element binding protein (CREB)-binding protein (CBP) and E1A interacting protein of 300 kDa (EP300 or P300) [CBP/P300] inhibitor. The activity of NEO2734 in a spectrum of hematological malignancies and solid tumors, relative to that of traditional BET inhibitors, have been presented at EHA (European Hematology Association) and ESMO (European Society for Medical Oncology) 2018, with a forthcoming presentation at ASH (American Society of Hematology) in December 2018. Initial clinical studies of NEO2734 in patients with cancer are planned for 2019. NEO2734's Targets